HHS’ oversight policy, developed in 2017, requires funding agencies to refer proposed research “reasonably anticipated” to create or involve high-risk pathogens to the department for an additional analysis of risks and benefits. However, the GAO found the framework for such reviews “allows for subjective and potentially inconsistent interpretations,” which leaves HHS “without assurance the department is reviewing all necessary research proposals.”
The office recommended HHS develop a clear standard of what “reasonably anticipated” means to ensure consistency in reviewing high-risk research, among other recommendations.
View the full report here.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
